TD Asset Management Inc. Sells 264 Shares of PerkinElmer, Inc. (NYSE:PKI)

TD Asset Management Inc. lessened its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 0.7% in the third quarter, HoldingsChannel reports. The fund owned 39,063 shares of the medical research company’s stock after selling 264 shares during the period. TD Asset Management Inc.’s holdings in PerkinElmer were worth $6,769,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in shares of PerkinElmer by 41.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,530,556 shares of the medical research company’s stock valued at $1,162,793,000 after buying an additional 2,218,099 shares during the period. Amundi bought a new stake in shares of PerkinElmer in the second quarter valued at approximately $78,474,000. Assenagon Asset Management S.A. bought a new stake in shares of PerkinElmer in the third quarter valued at approximately $73,691,000. Goldman Sachs Group Inc. boosted its stake in shares of PerkinElmer by 18.2% in the second quarter. Goldman Sachs Group Inc. now owns 1,413,500 shares of the medical research company’s stock valued at $218,258,000 after buying an additional 217,455 shares during the period. Finally, Balyasny Asset Management LLC boosted its stake in shares of PerkinElmer by 426.6% in the second quarter. Balyasny Asset Management LLC now owns 259,388 shares of the medical research company’s stock valued at $40,052,000 after buying an additional 210,127 shares during the period. Institutional investors own 80.93% of the company’s stock.

Shares of NYSE:PKI opened at $178.47 on Friday. The company has a fifty day moving average of $185.47 and a 200-day moving average of $178.45. The company has a market capitalization of $22.52 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 0.63 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.40 and a current ratio of 1.97. PerkinElmer, Inc. has a 52-week low of $119.95 and a 52-week high of $203.16.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Tuesday, November 2nd. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.61. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1 billion. PerkinElmer had a net margin of 22.41% and a return on equity of 30.57%. During the same period in the prior year, the business earned $2.09 earnings per share. On average, equities analysts forecast that PerkinElmer, Inc. will post 10.97 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 11th. Investors of record on Friday, January 21st will be issued a $0.07 dividend. The ex-dividend date is Thursday, January 20th. This represents a $0.28 dividend on an annualized basis and a yield of 0.16%. PerkinElmer’s payout ratio is 2.79%.

Several brokerages recently issued reports on PKI. Robert W. Baird boosted their price target on PerkinElmer from $183.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, November 3rd. They noted that the move was a valuation call. Royal Bank of Canada boosted their price objective on shares of PerkinElmer from $49.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 17th. Wells Fargo & Company boosted their price objective on shares of PerkinElmer from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, December 14th. Finally, The Goldman Sachs Group began coverage on shares of PerkinElmer in a research report on Thursday, December 16th. They set a “neutral” rating and a $200.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $164.48.

In related news, insider Daniel R. Tereau sold 3,546 shares of the stock in a transaction on Thursday, December 9th. The stock was sold at an average price of $189.55, for a total value of $672,144.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

About PerkinElmer

PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments.

See Also: Dividend

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.